Dianthus Therapeutics Inc. (DNTH)
NASDAQ: DNTH · Pharmaceutical Preparations · New York, NY
Our rating: Neutral
Call changed from Cautious to Neutral at $86.03, low conviction, November 6, 2026.
Breaks if: The neutral call requires the pipeline to remain materially unresolved in both directions. It turns Cautious if a pivotal trial fails or a complete-response letter is issued — or if cash runway, once confirmed in a quarterly filing, falls below four quarters without new financing disclosed within the next two reporting periods. It turns Positive if a Phase 3 primary endpoint is met and the subsequent 10-Q confirms cash runway above eight quarters, shifting the story from an open binary to a durable near-term outcome.
Key figures
| Market value | $4.8B |
|---|---|
| Revenue, last 12 months | n/a |
| Net income, last 12 months | −$202M |
| Free cash flow, last 12 months | n/a |
| Price to earnings | n/a |
| Free cash flow yield | n/a |
| Dividend yield | 0.0% |
| Operating margin | n/a |
| Return on equity | −22.6% |
| Beta to the S&P 500 | 1.11 |
| Volatility, annualized | 65.2% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | n/a | n/a | $-0.81 | n/a |
| June 30, 2026 | n/a | n/a | $-0.90 | n/a |
| March 31, 2026 | n/a | n/a | $-0.85 | n/a |
| December 31, 2025 | $284000.00 | −78.6% | $-1.52 | n/a |
| September 30, 2025 | $396000.00 | −81.8% | $-0.97 | n/a |
| June 30, 2025 | $193000.00 | −89.6% | $-0.88 | n/a |
| March 31, 2025 | $1M | 33.1% | $-0.82 | n/a |
| December 31, 2024 | $1M | 190.2% | $-0.82 | n/a |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Diluted earnings per share are above zero: Claude 3%, Gemini 5%, Mistral 2%
12 ledger entries and 39 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.